Evidence map›Paper›PMID 39556726›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

IL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines.

Miguel C Sobral, Laura Cabizzosu, Shawn J Kang, Kyle Ruark, Alexander J Najibi, Ryan S Lane, Einat Vitner, Hamza Ijaz, Maxence O Dellacherie, Mason T Dacus and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Miguel C SobralJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.
Laura CabizzosuJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.
Shawn J KangJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.
Kyle RuarkJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.
Alexander J NajibiJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.
Ryan S LaneDepartment of Cancer Immunology, Genentech, Inc., South San Francisco, CA 94080.
Einat VitnerJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.ORCID 0000-0001-8578-8551
Hamza IjazWyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA 02215.
Maxence O DellacherieJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.
Mason T DacusJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.ORCID 0000-0002-2192-5382
Christina M TringidesJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.
Irene de LázaroJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.
Mikaël J PittetDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva CH-1211, Switzerland.
Sören MüllerDepartment of Cancer Immunology, Genentech, Inc., South San Francisco, CA 94080.
Shannon J TurleyDepartment of Cancer Immunology, Genentech, Inc., South San Francisco, CA 94080.
David J MooneyJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.ORCID 0000-0001-6299-1194

Funding

Biomaterial Cancer Vaccines that Generate Patient-Specific Antigen In SituR01CA223255 · NCI · HARVARD UNIVERSITY · PI MOONEY, DAVID J · 2018 to 2022
$2.1M
NCI NIH HHS R01 CA223255
6 · The paper itself

Abstract

One driver of the high failure rates of clinical trials for therapeutic cancer vaccines is likely the inability to sufficiently engage conventional dendritic cells (cDCs), the antigen-presenting cell (APC) subset that is specialized in priming antitumor T cells. Here, we demonstrate that, relative to vaccination with an injectable mesoporous silica rod (MPS) vaccine alone (Vax), combining MPS vaccines with CD122-biased IL-2/anti-IL-2 antibody complexes (IL-2cx) drives ~3-fold expansion of cDCs at the vaccination sites, vaccine-draining lymph nodes, and spleens of treated mice. Furthermore, relative to Vax alone, Vax+IL-2cx led to a ~3-fold increase in the numbers of CD8

Indexed as

Cancer VaccinesCD8-Positive T-LymphocytesInterleukin-2AnimalsCell Line, TumorDendritic CellsFemaleKiller Cells, NaturalMiceMice, Inbred C57BLCancer VaccinesInterleukin-2cancer vaccinedendritic cellIL-2

Identifiers

PMID39556726
PMCPMC11621762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.